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median progression-free survival and overall survival were 
10.0 months (95 % CI 7.8–12.3) and 34.6 months (95 % CI 
19.9–not estimable), respectively. Frequently encountered 
grade 3 and 4 adverse events in this study were aspartate 
aminotransferase elevation (23.4 %), alanine aminotrans-
ferase elevation (21.3 %), anorexia (12.8 %), neutropenia 
(10.6 %), fatigue (8.5 %) and anemia (6.4 %). Grade 3 or 4 
peripheral neuropathy was not observed.
Conclusion First-line treatment with XELOX plus bevaci-
zumab showed a promising response rate and an acceptable 
tolerability profile in the clinical practice of Japanese meta-
static colorectal cancer patients that included elderly patients.
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Abstract 
Background This study was designed to evaluate the effi-
cacy and safety of XELOX plus bevacizumab in a Japa-
nese metastatic colorectal cancer population that included 
elderly patients.
Methods This was a multicenter, single-arm, open-label 
prospective study. The major inclusion criteria were previ-
ously untreated metastatic colorectal cancer, presence of 
measurable lesions, age ≥20 years; Eastern Cooperative 
Oncology Group performance status of 0–2, and adequate 
organ function. Patients received bevacizumab (7.5 mg/kg 
on day 1) and XELOX (130 mg/m2 oxaliplatin on day 1 plus 
1,000 mg/m2 capecitabine b.i.d. on days 1–14) every 3 weeks. 
The primary endpoint was confirmed objective response rate.
Results The study included 47 patients (male/female 
30/17; median age 69 years; age range 38–81 years with 
10 patients ≥75 years; PS 0/1/2, 40/5/2) enrolled between 
May 2010 and March 2011. Responses were assessed 
in 46 eligible patients. The objective response rate was 
52.2 % (95 % confidence interval [CI] 37.0–67.1). The 
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Introduction
Colorectal cancer (CRC) is the second most common type 
of cancer and the third most common cause of cancer mor-
tality in Japan [1]. Surgical removal of metastatic CRC 
(mCRC) is usually difficult, making chemotherapy the first 
choice for treatment [2].
FOLFOX4, a bi-weekly regimen of intravenous bolus 
and infusional 5-fluorouracil/leucovorin (5-FU/LV) plus 
oxaliplatin, is widely used in patients with previously 
untreated mCRC [3]. Capecitabine, an oral fluoropyrimi-
dine, has shown efficacy similar to bolus 5-FU/LV as a 
first-line treatment for mCRC [4, 5]. Oral fluoropyrimi-
dines can replace the intravenous fluoropyrimidine compo-
nent of combination regimens. Capecitabine and a 3-week 
dose of oxaliplatin (the XELOX regimen) have also been 
shown to have efficacy similar to 5-FU/LV plus oxalipl-
atin (FOLFOX4 or FOLFOX6) for first-line treatment of 
mCRC patients [6, 7]. A pivotal phase III study (NO16966) 
reported that adding bevacizumab to oxaliplatin-based 
chemotherapy significantly improved progression-free sur-
vival (PFS) by 1.4 months when used as first-line treatment 
for mCRC [8]. XELOX plus bevacizumab is an effective 
treatment strategy with a manageable tolerability profile in 
Japanese patients with mCRC [9]. However, there are no 
prospective data in clinical practice concerning XELOX 
plus bevacizumab in Japan. The present study was designed 
to evaluate the efficacy and safety of XELOX plus beva-




This was a prospective, multicenter, single-arm, open-label 
study that was conducted to evaluate the efficacy and safety 
of the commonly used doses of XELOX plus bevacizumab 
in a Japanese mCRC population that included elderly 
patients. The primary endpoint was the objective response 
rate (ORR), and the secondary endpoints were PFS, overall 
survival (OS), and safety.
Eligibility
Patients with histologically proven, unresectable, advanced 
CRC or mCRC that was previously untreated were eligible 
for this study if they met the following criteria—measur-
able lesions based on Response Evaluation Criteria in Solid 
Tumors (RECIST), version 1.1 [10]; age ≥20 years; East-
ern Cooperative Oncology Group (ECOG) performance sta-
tus (PS) ≤2; life expectancy ≥3 months; no prior systemic 
chemotherapy for mCRC; no progression within 6 months 
of completion of adjuvant chemotherapy; adequate bone 
marrow function (neutrophil count ≥1,500/mm3, platelet 
count ≥100,000/mm3, and hemoglobin ≥9.0 g/dL); ade-
quate hepatic function [total bilirubin ≤2.0 mg/dL, aspar-
tate aminotransferase (AST) and alanine aminotransferase 
(ALT) ≤2.5 or 5 (in cases with liver metastases) times the 
institutional upper limit of normal]; adequate renal function 
(creatinine ≤1.5 mg/dL and protein urea ≤ grade 1); and 
written informed consent before enrollment in the study. 
The exclusion criteria included brain metastases; clini-
cally significant ascites and pleural effusion; major surgery, 
open biopsy, or significant traumatic injury within 4 weeks 
before enrollment; fine-needle aspiration biopsy or central 
venous line placement within 1 week before enrollment; 
bleeding diathesis or coagulopathy; non-healing bone 
fracture; diarrhea grade ≥2; uncontrolled hypertension or 
peptic ulcer; clinically significant cardiovascular disease; 
daily treatment with high-dose aspirin (≥325 mg/day) or 
non-steroidal anti-inflammatory medications; immune sup-
pressive or steroidal medications; and peripheral neuropa-
thy grade ≥1.
Treatment schedule
XELOX treatment included a 2-h intravenous infusion of 
130 mg/m2 oxaliplatin (Yakult Honsha Co., Ltd., Tokyo, 
Japan) on day 1 plus 1,000 mg/m2 oral capecitabine (Chu-
gai Pharmaceutical Co., Ltd., Tokyo, Japan) twice daily for 
2 weeks of a 3-week cycle. The first dose of capecitabine 
was administered in the evening on day 1, and the last 
dose was given in the morning on day 15. Patients received 
7.5 mg/kg bevacizumab (Chugai Pharmaceutical Co., Ltd.) 
as a 30–90-min intravenous infusion before oxaliplatin 
treatment on day 1 of the 3-week cycle. Treatment contin-
ued until disease progression, intolerable adverse events, or 
withdrawal of consent.
Treatment was interrupted if grade 2–4 toxicities were 
observed, and the delay continued until recovery in patients 
with neutrophil counts <1,500/mm3, febrile neutrope-
nia, platelet counts <75,000/mm3, or significant persistent 
non-hematological toxicities. Oxaliplatin was skipped if 
grade ≥2 neurotoxicity was observed and bevacizumab 
was skipped if grade ≥2 protein urea was observed. Doses 
were modified based on hematological parameters and the 
degree of non-hematological toxicities. The capecitabine 
dose was reduced to 800 mg/m2 (or further to 600 mg/
m2) if patients experienced grade 3 or 4 diarrhea, stomati-
tis, nausea or vomiting, anorexia, dermatitis, grade 4 neu-
tropenia, or grade 3 or 4 thrombocytopenia. Oxaliplatin 
was also reduced to 100 mg/m2 (or further to 85 mg/m2) 
for all of the above conditions except for dermatitis, and 
was also reduced in cases of persistent (≥15 days) grade 2 
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neurotoxicity or temporary (8–14 days) grade 3 neurotoxic-
ity. In patients with persistent (≥15 days) grade 3 neuro-
toxicity or temporary grade 4 neurotoxicity, oxaliplatin was 
omitted from the regimen. No dose modifications were per-
formed for bevacizumab. This treatment plan was almost 
identical to that of the study NO16966 [8].
If oxaliplatin and/or bevacizumab were discontinued, 
treatment with the remaining components could be contin-
ued. For example, capecitabine could be administered with 
or without bevacizumab after discontinuation of oxaliplatin, 
and XELOX or capecitabine could be given after discontin-
uation of bevacizumab. However, continuation of oxaliplatin 
or bevacizumab without capecitabine was not permitted.
Efficacy and safety evaluation
Computed tomography scans were performed to assess 
tumors, starting within 4 weeks prior to study registration and 
repeated every 6 weeks. The investigators evaluated response 
rates according to RECIST, version 1.1 [10]. An independent 
review committee (IRC) confirmed the tumor responses. PFS 
was defined as the time from the date of registration to the 
date that disease progression was first confirmed, as deter-
mined by the IRC, or to the date of death from any cause. 
Data were censored at the last tumor assessment if a patient 
withdrew before progression was observed. OS was defined 
as the time from the date of registration to death. Treatment 
continued until disease progression, unacceptable toxicity, or 
patient withdrawal. All eligible patients were included in the 
response and survival analyses (N = 46).
Adverse events were assessed for all enrolled patients 
(N = 47) according to the Common Terminology Criteria 
for Adverse Events, version 4.0.
Relative dose intensity
Relative dose intensity can be decreased by reducing, delay-
ing or skipping the chemotherapy dose and was calculated 
according to the following equation: [total actual administered 
dose/actual administration period (final day of the treatment 
course − day of the administration + 1 days)/total planned 
dose/planned administration period (21 days)] × 100.
Statistical consideration
We examined whether the combination of XELOX plus 
bevacizumab could achieve a higher ORR than other chem-
otherapy regimens, as has been observed in other coun-
tries, in Japanese patients. In view of previous studies, we 
assumed a threshold ORR of 30 % and an expected value 
of at least 50 %. Under these assumptions, we determined 
that 39 patients were needed to provide a one-sided alpha 
of 0.05 and 80 % power. Factoring in a 5 % dropout rate 
and the possibility of ineligible patients, we set a target 
sample size of 41 patients. Registration was scheduled to 
continue for 12 months, and we planned to follow-up the 
patients for 36 months after the last registration. The 95 % 
CIs for the response rates were estimated by the Clop-
per−Pearson exact method. The PFS and OS curves were 
estimated by the Kaplan–Meier method, and their CIs were 
estimated using the Brookmeyer and Crowley method. All 
statistical analyses were performed using the SAS for Win-
dows, release 9.3 (SAS Institute, Cary, NC, USA).
Ethics
The ethical, medical, and scientific aspects of the study 
were reviewed and approved by the ethics committee of 
each participating institution in the UMIN clinical tri-
als registry (UMIN000003915). The study was conducted 




A total of 47 patients were enrolled in the study between 
May 2010 and March 2011. One patient did not meet the 
eligibility criteria. Therefore, ORR, OS, and PFS were 
evaluated in 46 patients, while toxicity was evaluated in 47 
patients treated with XELOX plus bevacizumab.
The characteristics of the 47 patients are described in 
Table 1. The population included 30 male and 17 female 
patients with a median age of 69 years (range 38–81). 
Twenty of the 47 patients (42 %) were ≥70 years old, and 
10 patients (21 %) were ≥75 years old. The ECOG PS was 
0 in 40 patients (85 %), 1 in 5 patients (11 %), and 2 in 2 
patients (4 %). Affected organs were the liver in 35 patients 
(75 %), the lung in 10 patients (21 %), the lymph nodes in 
16 patients (34 %), and the peritoneum in 7 patients (15 %). 
The liver was the most common site of metastasis.
Treatment duration
The median duration of treatment was 5.0 months (range 
0.7–20.0) with a median of 6.0 treatment cycles (range 
1–28). XELOX plus bevacizumab combination therapy was 
administered for a median of 5 cycles (range 1–16). After 
discontinuing oxaliplatin, 3 patients (6.4 %) continued with 
capecitabine and bevacizumab combination therapy and a 
received a median of 5 cycles (range 3–20). A total of 22 
patients (46.8 %) received XELOX therapy for a median of 
1 cycle (range 1–4) during permanent or temporary discon-
tinuation of bevacizumab.
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Based on the planned dose intensities of 1,000 mg/m2 
capecitabine twice daily for 2 weeks of a 3-week cycle, 
130 mg/m2 oxaliplatin per 3-week cycle, and 7.5 mg/kg 
bevacizumab per 3-week cycle, the median relative dose 
intensities of oxaliplatin and bevacizumab were 79.0 % 
(95 % CI 42.4–98.1) and 75.9 % (95 % CI 41.6–96.2), 
respectively.
Efficacy
The results of the tumor response analysis are shown in 
Table 2. A complete response (CR) was observed in 1 patient 
(2.2 %) and a partial response (PR) was observed in 23 
patients (50.0 %) giving an overall response rate (CR + PR) 
of 52.2 % (95 % CI 37.0–67.1). Stable disease (SD) was 
observed in 15 additional patients (32.6 %). Therefore, the 
overall disease control rate (CR + PR + SD) was 84.8 % 
(95 % CI 71.1–93.7). The response rate across all time points 
without confirmation was 67.4 % (95 % CI 52.0–80.5).
The cut-off date for PFS and OS was April 2014. The 
median follow-up period was 34.4 months. Median PFS was 
10.0 months (95 % CI 7.8–12.3; Fig. 1). A total of 27 of 
the 46 eligible patients died due to progression of advanced 
colorectal cancer. At the time of analysis, the median OS 
was 34.6 months (95 % CI 19.9–not estimable; Fig. 2).
Safety
Toxicity data are available for 47 patients treated with 
a median of 6.0 chemotherapy cycles (range 1–28). 
Toxicities are summarized in Table 3. Frequently encoun-
tered non-hematological toxicities included peripheral 
neuropathy, hand-foot syndrome, skin hyperpigmenta-
tion, fatigue, and gastrointestinal adverse effects such as 
diarrhea. Most of the non-hematological toxicities were 
grade 1 or 2. Frequently encountered adverse effects 
included grade 3 or 4 anorexia and fatigue, which were 
recorded in 6 (12.8 %) and 4 (8.5 %) of the 47 patients, 
respectively. No grade 3 or 4 peripheral neuropathy was 
observed. Other grade 3 or 4 non-hematological toxicities 
Table 1  Patient characteristics 
(N = 47)
ECOG Eastern Cooperative Oncology Group
Factor Characteristic N
Sex Male 30 (64 %)
Female 17 (36 %)
Age Median 69
Range 38–81
Performance status (ECOG) 0 40 (85 %)
1 5 (11 %)
2 2 (4 %)
Primary tumor histology Well-differentiated adenocarcinoma 7 (15 %)
Moderately differentiated adenocarcinoma 23 (49 %)
Poorly differentiated adenocarcinoma 6 (13 %)
Other 2 (4 %)
Unknown 9 (19 %)
Affected organs Liver 35 (74 %)
Lung 10 (21 %)
Lymph nodes 16 (34 %)
Peritoneum 7 (15 %)
Local recurrence 3 (6 %)
Other 5 (11 %)
Table 2  Tumor responses (N = 46)
OPR = (CR + PR), DCR = (CR + PR + SD)
CI confidence interval, CR complete response, DCR disease control 
rate, NE not evaluable, ORR overall response rate, PD progressive 
disease, PR partial response, RECIST Response Evaluation Criteria in 








 90 % CI 39.2–65.0
 95 % CI 37.0–67.1
DCR 39 (84.8)
 95 % CI 71.1–93.7
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were febrile neutropenia, nausea, hand-foot syndrome, 
and oral mucositis, each of which occurred in 1 patient. 
With regard to hematological toxicities, including labo-
ratory disorders, frequently encountered toxicities were 
grade 3 or 4 neutropenia, leukopenia, thrombocytope-
nia, anemia, and elevation of AST and ALT, which were 
recorded in 5 (10.6 %), 2 (4.3 %), 2 (4.3 %), 3 (6.4 %), 
11 (23.4 %), and 10 (21.3 %) of the 47 patients, respec-
tively. Frequently encountered bevacizumab-related tox-
icities were hypertension in 22 patients (46.8 %) and 
proteinuria in 20 patients (47.6 % of 42 patients). Other 
bevacizumab-related toxicities included a thromboem-
bolic event, gastrointestinal hemorrhage, and gastroin-
testinal perforation, each of which occurred in 1 patient 
(2.1 %).
A total of 15 patients (31.9 %) discontinued the protocol 
because of adverse events—5 patients with neurosensory 
toxicity, 4 patients with anorexia, 4 patients with fatigue, 
2 patients with neutropenia, 2 patients with hypertension, 
1 patient with gastrointestinal hemorrhage, 1 patient with 
diarrhea, 1 patient with a thromboembolic event, and 1 
patient with hand-foot syndrome.
Fig. 1  Kaplan–Meier estimate 
for progression-free survival 
(PFS). After a median follow-up 
time of 34.4 months, the median 
PFS was 10.0 months (95 % CI 
7.8–12.3)
Fig. 2  Kaplan–Meier estimate 
for overall survival (OS). The 
median OS was 34.6 months 
(95 % CI 19.9–not estimable)
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Post‑treatment
After treatment with XELOX plus bevacizumab, 18 
patients (38.3 %) underwent surgery and 4 patients 
(8.5 %) received radiation therapy. Thirty-six of the 47 
patients (76.6 %) were treated with second-line chemo-
therapy, and 21 of those 36 patients (58.3 %) received 
bevacizumab continuously. Two patients received com-
bination chemotherapy with anti-epidermal growth fac-
tor receptor (EGFR) antibody as second-line treatment, 
and 13 patients received the anti-EGFR antibody alone 
or in combination with cytotoxic agents after second-line 
chemotherapy. Seven patients (14.9 %) were treated with 
best supportive care.
Efficacy analyses according to age
A summary of efficacy according to patient age (≥70 
vs <70 years) is shown in Table 4. There were no signifi-
cant differences in ORR (42.1 vs 59.3 %, p = 0.370), PFS 
(9.7 vs 12.3 months, p = 0.179), or OS (23.2 months vs not 
reached, p = 0.069) based on patient age.
Safety analyses according to age
A summary of safety according to age (≥70 vs <70 years) 
is shown in Table 5. The toxicity profile in elderly patients 
was similar to that in younger patients, with the exceptions 
of neutropenia and leukopenia; elderly patients had lower 
rates of neutropenia and leukopenia than younger patients.
Discussion
Previous randomized and observational trials that have 
included the XELOX plus bevacizumab regimen as first-
line therapy have been mainly conducted in North Amer-
ica and Europe [8, 11, 12]. The NO16966 study [8, 13] 
reported longer median PFS (9.3 vs 7.4 months; hazard 
ratio 0.77; 95 % CI 0.6–0.94; p = 0.0026) and median 
Table 3  Adverse events related 
to treatment (N = 47)
ALT alanine aminotransferase, AST aspartate aminotransferase, ALT alkaline phosphatase
Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 3/4
Febrile neutropenia 0 (0.0 %) 0 (0.0 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
Fatigue 17 (36.2 %) 5 (10.6 %) 4 (8.5 %) 0 (0.0 %) 4 (8.5 %)
Diarrhea 14 (29.8 %) 7 (14.9 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Nausea 15 (31.9 %) 9 (19.1 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
Vomiting 8 (17.0 %) 2 (4.3 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Anorexia 16 (34.0 %) 9 (19.1 %) 6 (12.8 %) 0 (0.0 %) 6 (12.8 %)
Alopecia 1 (2.1 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Hand-foot syndrome 18 (38.3 %) 6 (12.8 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
Oral mucositis 14 (29.8 %) 1 (2.1 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
Dysgeusia 13 (27.7 %) 3 (6.4 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Skin hyperpigmentation 20 (42.6 %) 1 (2.1 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Hypersensitivity 1 (2.1 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Peripheral neuropathy 21 (44.7 %) 18 (38.3 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Blood bilirubin increased 10 (21.3 %) 7 (14.9 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
AST increased 19 (40.4 %) 4 (8.5 %) 10 (21.3 %) 1 (2.1 %) 11 (23.4 %)
ALT increased 14 (29.8 %) 4 (8.5 %) 9 (19.1 %) 1 (2.1 %) 10 (21.3 %)
ALP increased (N = 45) 19 (42.2 %) 2 (4.4 %) 1 (2.2 %) 0 (0.0 %) 1 (2.2 %)
Creatinine increased 10 (21.3 %) 2 (4.3 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
Leukopenia 15 (31.9 %) 14 (29.8 %) 2 (4.3 %) 0 (0.0 %) 2 (4.3 %)
Neutropenia 8 (17.0 %) 23 (48.9 %) 5 (10.6 %) 0 (0.0 %) 5 (10.6 %)
Thrombocytopenia 23 (48.9 %) 7 (14.9 %) 2 (4.3 %) 0 (0.0 %) 2 (4.3 %)
Anemia 28 (59.6 %) 12 (25.5 %) 2 (4.3 %) 1 (2.1 %) 3 (6.4 %)
Hypertension 9 (19.1 %) 11 (23.4 %) 2 (4.3 %) 0 (0.0 %) 2 (4.3 %)
Thromboembolic event 0 (0.0 %) 0 (0.0 %) 0 (0.0 %) 1 (2.1 %) 1 (2.1 %)
Proteinuria (N = 42) 14 (33.3 %) 6 (14.3 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Gastrointestinal hemorrhage 0 (0.0 %) 0 (0.0 %) 1 (2.1 %) 0 (0.0 %) 1 (2.1 %)
Gastrointestinal perforation 0 (0.0 %) 1 (2.1 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
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OS (21.6 vs 18.8 months) in the XELOX plus bevaci-
zumab arm than in the XELOX plus placebo arm in a 
subgroup analysis. Furthermore, another phase III trial 
(CAIRO2) reported an ORR of 50.0 %, a median PFS of 
10.7 months, and a median OS of 20.3 months in patients 
receiving XELOX plus bevacizumab [11]. In this prospec-
tive clinical study of Japanese mCRC patients that included 
elderly patients, XELOX plus bevacizumab achieved simi-
lar efficacy and safety as previous pivotal phase III stud-
ies of XELOX plus bevacizumab [8, 13], even in elderly 
patients. The ORR was 52.2 % (95 % CI 37.0–67.1). The 
median PFS and median OS were 10.0 months (95 % CI 
7.8–13.8) and 34.6 months (95 % CI 19.9–not estima-
ble), respectively. These outcomes are also similar to the 
favorable results from the phase I/II Japanese clinical trial 
of XELOX plus bevacizumab in mCRC patients (median 
PFS 11.0 months; median OS 27.4 months) [9] and to the 
results from a retrospective analysis of XELOX plus beva-
cizumab in clinical practice for Japanese mCRC patients 
(median PFS 290 days; median OS 816 days) [14].
Recent phase III trials as first-line chemotherapy plus 
biologics for mCRC patients yielded a favorable median 
OS of approximately 30 months [15, 16]. The OS in the 
present study was also favorable (34.6 months), as was 
the phase I/II Japanese clinical trial [9]. One reason for 
the favorable OS in our study may be that most patients 
received sequential therapy such as chemotherapy, radi-
otherapy, and surgery. A total of 21 patients (58.3 %) 
received bevacizumab-containing regimens as second-
line chemotherapy in our study. Therefore, improved OS 
might partially depend on the sequential use of bevaci-
zumab beyond disease progression [17], as it reportedly 
resulted in statistically significant increases in OS as sec-
ond-line therapy in combination with irinotecan or oxali-
platin-based regimens. Phase III studies of another class 
of biologics, anti-EGFR antibodies (cetuximab and pani-
tumumab), showed improved OS in patients with mCRC 
for whom other treatments had failed [18, 19]. In our 
study, 2 patients received anti-EGFR antibody-containing 
regimens as second-line therapy, and 13 patients received 
an anti-EGFR antibody alone or in combination with 
cytotoxic agents after second-line therapy. The anti-EGFR 
antibodies may have partially contributed to the improve-
ment in OS.
Table 4  Summary of treatment 
efficacy according to age
CI confidence interval, NE not estimable, ORR overall response rate, OS overall survival, PFS progression-
free survival, RECIST Response Evaluation Criteria in Solid Tumors
Responses (RECIST-
confirmed)
N Events ORR (%) 95 % CI p value (fisher’s 
exact test)
≥70 years 19 8 42.1 20.3–66.5  0.3695
<70 years 27 16 59.3 38.8–77.6
PFS N Median PFS (months) 95 % CI p value (log-
rank test)
≥70 years 19 9.7 6.4–11.4 0.1788
<70 years 27 12.3 7.2–14.5
OS N Median OS (months) 95 % CI p value (log-
rank test)
≥70 years 19 23.2 11.6–38.9  0.0688
<70 years 27 NE 19.9–NE
Table 5  Summary of safety 
according to age
≥70 years (N = 20) p value <70 years (N = 27)
All grades Grade 3/4 All grades All grades Grade 3/4
Leukopenia 10 (50.0 %) 1 (5.0 %) 0.0650 21 (77.8 %) 1 (3.7 %)
Neutropenia 11 (55.0 %) 3 (15.0 %) 0.0044 25 (92.6 %) 2 (7.4 %)
Thrombocytopenia 13 (65.0 %) 1 (5.0 %) 0.7583 19 (70.4 %) 1 (3.7 %)
Anemia 20 (100.0 %) 2 (10.0 %) 0.1256 23 (85.2 %) 1 (3.7 %)
Fatigue 12 (60.0 %) 2 (10.0 %) 0.7674 14 (51.9 %) 2 (7.4 %)
Diarrhea 10 (50.0 %) 0 (0.0 %) 0.5661 11 (40.7 %) 0 (0.0 %)
Anorexia 14 (70.0 %) 4 (20.0 %) 0.7583 17 (63.0 %) 2 (7.4 %)
Nausea 10 (50.0 %) 1 (5.0 %) 0.7729 15 (55.6 %) 0 (0.0 %)
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The toxicity profiles in our study were generally predict-
able and manageable. Elevated AST, increased ALT, and 
neutropenia were the most common grade 3 and 4 hema-
tologic toxicities; these events were observed in 23.4, 21.3, 
and 10.6 % of the patients, respectively. Anorexia and 
fatigue were the most common grade 3 and 4 non-hema-
tologic toxicities; these events occurred in 12.8 and 8.5 % 
of the patients, respectively. The incidence of other grade 
3 and 4 toxicities including neurotoxicity was extremely 
low. The incidences of grade 3 or 4 neurotoxicity were 
reportedly 15 [14] and 17 % [9] in the Japanese trials with 
XELOX plus bevacizumab. In a number of trials of oxalipl-
atin-based therapies, neurotoxicity was the most frequently 
encountered adverse event that led to discontinuation of 
treatment. In our study, no grade 3 or 4 neurotoxicity was 
observed, because an administration criterion of oxaliplatin 
was grade 0 or 1 neurotoxicity. However, the neurotoxic-
ity led to discontinuation of treatment in 5 of 47 patients 
(10.6 %). The overall rate of protocol discontinuation due 
to adverse events was 31.9 %, which might be acceptable.
The treatment schedule and doses selected for our 
study were identical to those in the NO16966 study [8, 
13]. The median relative dose intensities with considera-
tion of both dose reduction and treatment delay/skip in this 
study were acceptable. These could not be accurately com-
pared to those in the XELOX plus bevacizumab arm of the 
NO16966 study (ratio of dose received to dose planned), 
because there might be a difference in calculation method 
between the studies.
It is notable that 20 of the 47 patients enrolled in our trial 
were ≥70 years. Previous studies have established the effi-
cacy and safety of combination chemotherapy in elderly 
patients [20–22]. The addition of bevacizumab to chemother-
apy in geriatric populations has also been shown to be effec-
tive in observational cohort studies, subgroup analyses, and 
pooled analyses of cohorts from other randomized trials [23–
25]. A phase II study reported that an alternative XELOX 
plus bevacizumab (AXELOX) regimen was an effective and 
safe combination for elderly patients (age >70 years) with 
mCRC [26]. AXELOX treatment includes intravenous infu-
sion of 5 mg/kg bevacizumab, 85 mg/m2 oxaliplatin on day 
1, and 750 mg/m2 oral capecitabine twice daily for 1 week of 
a 2-week cycle. The AXELOX regimen achieved favorable 
efficacy (ORR 46.8 %; PFS 7.9 months; OS 20.1 months) 
and low toxicity (incidence of all grade 3 or 4 adverse 
events <10 %). The low toxicity of AXELOX is thought 
to be attributable to the low dose intensity of capecitabine, 
which is 56 % of the international standard dose of XELOX 
plus bevacizumab used in our study. However, in our study, 
the efficacy and safety for elderly patients ≥70 years were 
favorable in a manner similar to results achieved with 
younger patients <70 years. Our results suggest that the 
international standard dose of XELOX plus bevacizumab 
might be effective and safe for both younger and elderly Jap-
anese patients with mCRC. Moreover, the XELOX regimen 
requires only one visit per 3-week cycle for a 2- or 3-h infu-
sion, and no portable pump is required, which may provide 
a marked advantage over the FOLFOX regimen in terms of 
patient convenience.
In conclusion, this study found that first-line XELOX 
plus bevacizumab showed good tolerability and efficacy in 
clinical practice for the treatment of mCRC in a Japanese 
population that included elderly patients. XELOX plus bev-
acizumab may be considered a routine first-line treatment 
option for mCRC patients.
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